Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   BioPharma   /   Clinuvel, de droom van elke belegger......

BioPharma« Terug naar discussie overzicht

Clinuvel, de droom van elke belegger......

Volgen
2.596 Posts
Pagina: «« 1 ... 118 119 120 121 122 ... 130 »» | Laatste | Omlaag ↓
  1. frank2you 21 april 2016 15:27
    Van het sharescene forum, vind het een logisch verhaal :

    Clinuvel is building up an exclusive Distribution channel via the expert centers. Once it is set up, it is highly regulated and Cuv is the only company who controls it. By time, more indications will be approved and the expert centres become more and more well known as the "place to go" for anything in terms of medicinal photo protection. Competitors will not be able to get any foot in the door, and all data and knowledge is controlled and owned by Cuv. Cuv will be the well known expert in leader in this field. This will be highly profitable and highly shielded from competition. With all the data and safety records collected over time Cuv will be able to expand into more indications, put vitiligo and skin cancer protection in place and will be a multi billion usd company.

    That is my vision, and that's why I don't care if sales are starting in April or just in summer this year. Most important is to build a solid basis now and that's what our "best pharma manager" is doing.
  3. [verwijderd] 22 april 2016 11:31
    Deze?

    A few days ago, I was contacted by Jasmin who asked me to document a small demonstration and protest in Canary Wharf. As I was not teaching in the afternoon, I happily joined the team as one of the official photographers. I must admit I had never heard about the EPP health issue before so I would like to share what I have learnt today with you. EPP or Erythropoietic Protoporphyria is a genetic disease that affects one person out of 100 000 (if I remember well). Symptoms include acute pain and severe burns after a direct exposure to sunlight or halogen lights. Patients often have to stay in darkness or at least protect themselves from the sun (with hats, umbrellas, scarves...). There is now a treatment for EPP but because of European regulations this is not yet available in Europe and treatment is too expensive. Today 21 patients and family members travelled to London to demonstrate and protest, walking from West India Quay to the European Medecine's Agency in Canary Wharf.
    I was really glad I could join the group and happily wore the beautiful bright t-shirt. This made me realise how much I love this type of photography with a social and humane purpose: Documentary photography.
  5. frank2you 22 april 2016 17:16
    quote:

    uptech schreef op 22 april 2016 11:31:

    Deze?

    A few days ago, I was contacted by Jasmin who asked me to document a small demonstration and protest in Canary Wharf. As I was not teaching in the afternoon, I happily joined the team as one of the official photographers. I must admit I had never heard about the EPP health issue before so I would like to share what I have learnt today with you. EPP or Erythropoietic Protoporphyria is a genetic disease that affects one person out of 100 000 (if I remember well). Symptoms include acute pain and severe burns after a direct exposure to sunlight or halogen lights. Patients often have to stay in darkness or at least protect themselves from the sun (with hats, umbrellas, scarves...). There is now a treatment for EPP but because of European regulations this is not yet available in Europe and treatment is too expensive. Today 21 patients and family members travelled to London to demonstrate and protest, walking from West India Quay to the European Medecine's Agency in Canary Wharf.
    I was really glad I could join the group and happily wore the beautiful bright t-shirt. This made me realise how much I love this type of photography with a social and humane purpose: Documentary photography.

    Lijkt me niet...op de foto's is duidelijk briefpapier van de EMA te zien.
  14. frank2you 11 mei 2016 13:11
    quote:

    uptech schreef op 11 mei 2016 11:44:

    Hoogste koers dit jaar: 4.45. Is Clinuvel eindelijk door een taaie weerstand heen?
    Persoonlijk vind ik TA komplete bullshit, tis achteraf verklaren wat er gebeurd is en heeft totaal geen voorspellende waarde. Die wordt vooral bepaalt door prijs per implantaat * aantal verkochte exemplaren + nieuwe ontwikkelingen.
  16. frank2you 17 mei 2016 17:18
    quote:

    uptech schreef op 17 mei 2016 10:21:

    Helemaal correct voorspellen kan natuurlijk ook niet, maar op basis van patronen uit het verleden zijn er wel overeenkomsten in koersbewegingen te vinden. En Bas Heijink van iex heeft het verassend vaak bij het rechte eind.
    Ook dat is niet waar. Bas H. heeft de gave om achteraf de koersontwikkeling in het verleden te verklaren. In de toekomst blijft ie wekenlang hetzelfde roepen waardoor op een gegeven moment zijn voorspelling vanzelfsprekend uitkomt.....alleen in een andere periode. Die periode houdt hij bewust vaag omdat hij zelf wel weet dat dat onmogelijk is. Anders zou iedereen die Bas volgt nu binnen zijn......TA is welkom in Utopia.....bullshit....nonsens. Leuk als hobby maar voor toekomstvoorspellingen en waarheidsvinding volstrekt waardeloos.
  20. [verwijderd] 18 mei 2016 10:28
    Update op de clinuvel site:
    SCENESSE® treatment in Europe
    German Porphyria Expert Centres to start distribution of SCENESSE® (afamelanotide 16mg) Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced an update on the company’s post-authorisation distribution of SCENESSE® (afamelanotide 16mg) across Europe for adult patients with the rare disorder erythropoietic protoporphyria (EPP).1 SCENESSE® in EPP SCENESSE® is the first approved treatment for EPP, a genetic disorder characterised by acute phototoxic reactions (anaphylactoid reactions and burns) and forced withdrawal from exposure to all forms of visible light. Clinuvel conducted clinical trials of SCENESSE® in EPP from 2006 to 2013. During this time the company evaluated the treatment in…

    Dat is goed nieuws !
2.596 Posts
Pagina: «« 1 ... 118 119 120 121 122 ... 130 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
AALBERTS NV 36,380 +2,00 +5,82%
B&S Group SA 4,570 +0,22 +5,06%
AZERION 1,226 +0,04 +3,72%
Aegon 6,102 +0,20 +3,42%
BAM 4,064 +0,13 +3,20%
HEIJMANS KON 29,000 +0,80 +2,84%
ASML 658,400 +15,50 +2,41%
ASMI 511,400 +11,20 +2,24%
JUST EAT TAKEAWAY 15,110 +0,33 +2,23%
BESI 113,000 +2,30 +2,08%
ALLFUNDS GROUP 5,585 +0,11 +2,01%
PROSUS 38,550 +0,64 +1,70%
ASR Nederland 45,300 +0,69 +1,55%
Sif Holding 12,440 +0,18 +1,47%
RENEWI 9,670 +0,13 +1,36%
WDP 20,920 +0,28 +1,36%
NX FILTRATION 4,000 +0,04 +1,14%
TomTom 5,275 +0,06 +1,05%
UMG 22,810 +0,23 +1,02%
ASCX 1.226,78 +12,12 +1,00%
ArcelorMittal 23,840 +0,22 +0,93%
SIGNIFY NV 21,180 +0,18 +0,86%
NN Group 43,970 +0,35 +0,80%
AMX 870,28 +6,88 +0,80%
ForFarmers 3,230 +0,02 +0,78%
Pharming 0,731 +0,00 +0,62%
AEX 881,73 +5,15 +0,59%
Wolters Kluwer 157,950 +0,90 +0,57%
Vopak 44,300 +0,24 +0,54%
Accsys 0,580 +0,00 +0,52%
Galapagos 26,260 +0,12 +0,46%
ABN AMRO BANK N.V. 14,715 +0,06 +0,44%
ADYEN NV 1.378,400 +6,00 +0,44%
Fagron 18,680 +0,08 +0,43%
ING 14,658 +0,06 +0,42%
THEON INTERNAT 10,500 +0,04 +0,38%
EXOR NV 93,650 +0,35 +0,38%
Kendrion 10,840 +0,04 +0,37%
INPOST 16,580 +0,06 +0,36%
Arcadis 62,450 +0,20 +0,32%
RELX 44,580 +0,14 +0,32%
NSI 19,740 +0,06 +0,30%
Corbion 21,980 +0,06 +0,27%
TKH 30,780 +0,08 +0,26%
Akzo Nobel 55,300 +0,14 +0,25%
Vastned 24,600 +0,05 +0,20%
DSM FIRMENICH AG 103,950 +0,20 +0,19%
SBM Offshore 17,120 +0,03 +0,18%
SHELL PLC 30,720 +0,05 +0,16%
CTP 15,200 +0,02 +0,13%
ACOMO 17,500 +0,02 +0,11%
IMCD 142,100 +0,15 +0,11%
Eurocommercial Properties 23,650 0,00 0,00%
Nedap N.V. 53,000 0,00 0,00%
Van Lanschot Kempen NV 42,450 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
EBUSCO HOLDING 1,045 -0,04 -3,37%
OCI 11,070 -0,29 -2,51%
Alfen N.V. 11,395 -0,29 -2,48%
PostNL 1,035 -0,02 -1,71%
Basic-Fit 21,260 -0,34 -1,57%
FASTNED 21,350 -0,25 -1,16%
Avantium 2,100 -0,02 -0,94%
Sligro 10,700 -0,08 -0,74%
Wereldhave 13,900 -0,08 -0,57%
Flow Traders 21,100 -0,12 -0,57%
AMG Critical Materials N.V. 14,290 -0,08 -0,56%
JDE PEET'S 18,870 -0,10 -0,53%
UNILEVER PLC 56,580 -0,24 -0,42%
CM.COM 5,880 -0,02 -0,34%
Air France-KLM 7,394 -0,02 -0,32%
Aperam 27,160 -0,08 -0,29%
Philips Koninklijke 25,790 -0,06 -0,23%
Brunel 8,800 -0,02 -0,23%
KPN 3,671 -0,01 -0,19%
Heineken 70,060 -0,08 -0,11%
Ahold Delhaize 32,650 -0,03 -0,09%
Fugro 17,200 -0,01 -0,06%
RANDSTAD NV 41,610 -0,01 -0,02%
vlag naam koers verschil relatief verschil
AEX 881,73 +5,15 +0,59%
AEX GR 3.458,42 +20,18 +0,59%
Germany40^ 19.647,00 +221,27 +1,14%
FTSE 100 8.287,30 +6,08 +0,07%
EURO50 4.796,20 0,00 0,00%
US30^ 44.913,70 0,00 0,00%
Nasd100^ 20.905,80 0,00 0,00%
US500^ 6.031,05 0,00 0,00%
Japan225^ 38.259,30 0,00 0,00%
VD-NEW 14,63 -0,50 -3,29%
#/^ Index indications calculated real time, zie disclaimer